Given the importance of CXCL12/CXCR4 signaling in B-ALL progression, the pharmacological inhibition of this signaling has been proposed to disrupt the cross talk between B-ALL cells and the protective stroma. This evidence concerns the gene CXCL12 and precursor B-cell acute lymphoblastic leukemia.